CYP2C9 is a genetically polymorphic human cytochrome P450 isozyme involved in the oxidative metabolism of many drugs, including nonsteroidal anti-inflammatory compounds. Individuals genotyped heterozygous or homozygous for CYP2C9 allelic variants have demonstrated altered metabolism of some drugs primarily metabolized by CYP2C9. The ability to expand screening of CYP2C9 allelic variants to a larger set of drugs and pharmaceutical agents would contribute to a better understanding of the significance of CYP2C9 polymorphisms in the population and to predictions of possible outcomes. The authors report the development of an in vitro fluorescence-based assay employing recombinant CYP2C9 variants (CYP2C9*1, CYP2C9*2, and CYP2C9*3) and fluorogenic Vivid ® CYP2C9 substrates to explore the effects of CYP2C9 polymorphisms on drug metabolism, using drugs primarily metabolized by CYP2C9. Several chemically diverse fluorogenic substrates (Vivid ® CYP2C9 blue, green, and red substrates) were used as prototypic probes to obtain in vitro CYP2C9 metabolic rates and kinetic parameters, such as apparent K m , V max , and V max /K m ratios for each allelic variant. In addition, a diverse panel of drugs was screened as assay modifiers with CYP2C9*1, CYP2C9*2, CYP2C9*3, and the fluorogenic Vivid ® CYP2C9 substrates. The inhibitory potential of this large group of chemically diverse drugs and compounds has been assessed on the basis of their ability to compete with Vivid ® CYP2C9 substrates in fluorescent reporter assays, thus providing a sensitive and quick assessment of polymorphism-dependent changes in CYP2C9 metabolism. (Journal of Biomolecular Screening 2004:439-449) 
INTRODUCTION
C YTOCHROME P450 ENZYMES (P450s) are a major class of human drug-metabolizing enzymes involved in oxidative metabolism of more than 50% of all clinically administered drugs and medications. 1, 2 Many clinically important P450 isozymes have numerous functional polymorphisms, including pseudogenes, gene deletions, and gene duplications 3, 4 that can affect metabolism of some drugs, leading to toxic effects and adverse drug reactions (ADRs) in individuals with the polymorphic variants of these isozymes. Individuals with specific P450 allelic variants may experience either toxic accumulation of certain drugs and/or their metabolites, resulting in increased toxicity and elevated probabil-ity of drug-drug interactions 5 or reduced therapeutic efficacy. 6, 7 However, these effects are both drug and polymorphism dependent, which means that individuals with certain P450 polymorphic variants may exhibit unaltered metabolic rates and toxicity levels for some drugs. The ability to effectively predict which drugs can be potentially problematic for individuals with P450 polymorphic variants would greatly benefit existing therapeutic practices and clinical trials. Consequently, assays that can effectively screen compounds against various P450 polymorphic isozymes, rather than only wild-type enzymes, have an additional benefit in that they may more accurately reflect the effect of polymorphism variances in the population and therefore can help prevent the waste of valuable research time and money on compounds that later become problematic or toxic in preclinical and clinical trials. In addition, information about changes in drug metabolism due to the presence of P450 polymorphisms can serve as a basis for a personalized therapeutic program (an individualized medication plan based on the patient's P450 metabolic profile) [8] [9] [10] and enhance drug efficacy for the responsive population.
CYP2C9 is the principal human cytochrome P450 isozyme involved in the oxidative metabolism of a wide array of clinically important drugs such as (S)-warfarin, losartan, phenytoin, sulphamethoxazole, tolbutamide, and numerous nonsteroidal antiinflammatory drugs. 11, 12 Several polymorphic variants of CYP2C9 have been described, including single-nucleotide polymorphisms in the coding region of CYP2C9. 13 The wild-type allele, CYP2C9*1, is the most common in humans. CYP2C9*2 and CYP2C9*3 represent a single-nucleotide polymorphism resulting in a single amino acid substitution: CYP2C9*2 with a point mutation in exon 3, causing an Arg144Cys exchange, and CYP2C9*3 with a point mutation in exon 7, resulting in an Ile359Leu exchange. 13, 14 The frequency of these polymorphisms depends on population ethnicity, being the highest among Caucasians with allele frequencies of CYP2C9*1, CYP2C9*2, and CYP2C9*3 in the range of 0.79 to 0.86, 0.08 to 0.125, and 0.03 to 0.085, respectively. 7, 15 Subjects genotyped heterozygous or homozygous for the allelic variants CYP2C9*2 (Cys144) and CYP2C9*3 (Leu359) exhibit altered metabolism for some drugs primarily metabolized by CYP2C9, such as (S)-warfarin [16] [17] [18] and cyclophosphamide, 19 but unaltered metabolism for other drugs known to be metabolized by CYP2C9, such as diclofenac, 20 suggesting that the effects of CYP2C9 polymorphisms on drug metabolism tend to be substrate specific. Nonetheless, an understanding of the full implications of CYP2C9 polymorphisms in human drug metabolism remains incomplete, partially due to the lack of a systematic approach that would allow successful predictions of changes in substrate specificity or metabolic rates for each polymorphic variant.
The high percentage of these CYP2C9 polymorphic variants in the human population, as well as their connection to interindividual drug metabolism variability, emphasizes the need for functional screening of drugs and drug candidates in development with these polymorphic variants. Therefore, reliable highthroughput assays with the ability to expand screening of CYP2C9 allelic variants to a large set of drugs and compounds would be a major contribution to the investigation of CYP2C9 polymorphisms, enabling prediction of possible outcomes in future clinical trials.
Here we report the development of fluorescence-based HTS assays employing baculovirus-expressed CYP2C9*1, CYP2C9*2, and CYP2C9*3 variants and the fluorogenic Vivid ® CYP2C9 blue, green, and red substrates. These assays were applied to in vitro comparative assessment of CYP2C9 drug metabolism with the polymorphic variants of this isozyme, including kinetic parameters, solvent sensitivity, and screening for the inhibitory potential of a selected panel of clinically important drugs. The possibility of using these assays as a first-line approach for the evaluation of the significance of CYP2C9 polymorphisms, as well as their impact on drug metabolism and toxicity, is further discussed.
METHODS

Chemicals
All reagents used were of the highest commercial grade available. The Vivid ® CYP2C9 blue, green, and red substrates; their corresponding fluorescent dye standards; and NADP + were obtained from PanVera (Madison, WI). (S)-Warfarin was obtained from Ultrafine (Manchester, UK). All other chemicals were obtained from Sigma-Aldrich Corp (St. Louis, MO).
Enzymes
Microsomes from baculovirus-infected cells coexpressing 1 of the CYP2C9*1, CYP2C9*2, and CYP2C9*3 allelic variants together with NADPH-cytochrome P450 reductase (BACULOSOMES ® ), as well as an NADPH regeneration system (glucose-6-phosphate and glucose-6-phosphate dehydrogenase), were obtained from PanVera.
Generation of standard curve with fluorescent dye standard
All measurements were acquired at room temperature in Costar ® black, flat-bottom 96-well plates (Corning Incorporated Life Sciences, Acton, MA) with a total calibration volume of 0.1 mL/well. A stock solution of the fluorescent dye standard was prepared, serial dilutions were made, and fluorescence values were collected, following PanVera's Vivid ® Assay Protocol, as described at http://www.invitrogen.com/content/sfs/panvera/ L0504.pdf. Fluorescence values were determined with a GEMINI XS fluorescence plate reader (Molecular Devices Corporation, Sunnyvale, CA), using the settings given in Table 1 .
The data were plotted to a corresponding calibration curve, which was then used to calculate the concentration of oxidized substrate formed from the observed changes in fluorescence intensity (relative fluorescence units [RFUs] ).
Assay incubation conditions
The reactions were performed in Costar ® black, flat-bottom 96well plates with a total reaction volume of 0.1 mL/well. All incubations were performed under conditions shown to be linear with respect to protein and substrate concentration. The plates were in- 
Apparent V max and K m determination
The assays for determining kinetic parameters for the CYP2C9 (*1, *2, or *3) reaction with the Vivid ® CYP2C9 blue, green, and red substrates were performed essentially as described in the Assay Incubation Conditions section, except that the substrate concentrations were varied for these determinations. The reaction rates were measured by following the increase in RFUs over the course of the reaction and using the calibration curve generated from the corresponding fluorescent dye standard. The kinetic parameters for the reactions were obtained by curve fitting and analysis using Prism ® software (GraphPad Software, Inc., San Diego, CA).
Determining apparent K i values
All assays were performed under conditions shown to be linear with respect to protein and substrate concentration and time fol-lowing PanVera's Vivid ® assay protocol. These assays were performed essentially as described in the Assay Incubation Conditions section. Following this method, a selected panel of drugs (see Table 3 ) was screened. The apparent K i values for these drugs were determined as listed in Table 3 . Sulfaphenazole, tolbutamide, piroxicam, ibuprofen, phenytoin, and lansoprazole were initially prepared as stock solutions in ACN and serially diluted with water before addition to the reaction to create dose-response curves. Controls were included to account for possible solvent inhibition. Diclofenac, glipizide, (R,S)-warfarin, and (S)-warfarin were prepared as aqueous stock solutions prior to serial dilution in water. Dose-response curves were generated to cover a range appropriate for determination of apparent K i values (at least 4 orders of magnitude) but not exceeding 1 mM. The apparent K i values were calculated using Prism ® software.
Solvent effects
The effects of varying the concentrations of several organic solvents (ethanol [EtOH], methanol [MeOH], DMSO, and ACN) on the Vivid ® CYP2C9 blue, green, and red assays were explored. The assays were performed essentially as described in the Assay Incubation Conditions section, but each reaction contained varying amounts of 1 of the solvents (0%-1% levels (v/v)), and each assay was run for 10 min.
Dynamic range and Z factor
The assays for these experiments were performed essentially as described in the Assay Incubation Conditions section, but were run for 30 min. The dynamic range was calculated as a net fold increase in fluorescence signal intensity over the background signal. The Z′ factor was determined as described by Zhang and coworkers. 21 
RESULTS
General principles of the metabolism of fluorogenic Vivid ® substrates by cytochrome P450
The general principles of the fluorescence-based assay using Vivid ® substrates have been described previously. 22, 23 Figure 1 provides a schematic representation of the conversion of the fluorogenic Vivid ® substrate into a fluorescent product upon oxidation by a specific P450 isozyme. Initially nonfluorescent, the Vivid ® substrate is converted into a highly fluorescent dye as a result of metabolism by a specific P450 isozyme, and P450 activity is monitored by measuring the time-dependent net increase in fluorescence signal (fluorescent reporter reaction). Measuring inhibition of the signal in the fluorescent reporter reaction in the presence of competitive drugs or compounds (assay modifiers) allows detection of isozyme-specific substrates and inhibitors.
Comparison of apparent kinetic parameters of baculovirus-expressed CYP2C9*1, *2, and *3
Kinetic parameters, such as apparent V max and K m values, are important measures of the interactions between a substrate and its metabolizing enzyme and can also be used for the estimation of intrinsic clearance rates, V max /K m . 24 CYP2C9 has demonstrated complex kinetic behavior in recombinant expression systems, indicating the ability of this isozyme to be involved in the metabolism of substrates belonging to diverse chemical groups. 25 Vivid ® CYP2C9 substrates, developed as benzoxymethyl and alkoxymethyl ethers of several phenolic dyes, such as resorufin (Vivid ® CYP2C9 red), fluorescein (Vivid ® CYP2C9 green), and 3cyano-7-hydroxycoumarin (Vivid ® CYP2C9 blue), represent a chemically diverse set of fluorogenic probes to study CYP2C9 metabolism and inhibition (http://gcms.invitrogen.com/content. cfm?pageid=10058). For that reason, we compared kinetic parameters, such as apparent K m and V max values, obtained in the metabolism reaction of baculovirus-expressed CYP2C9*1, *2, and *3 with several chemically unrelated fluorogenic Vivid ® CYP2C9 substrates (blue, green, and red).
Apparent kinetic parameters for the metabolism of fluorogenic Vivid ® CYP2C9 substrates (blue, green, and red) by CYP2C9*1, *2, and *3 are presented in Table 2 . Up to a 2-fold increase in the apparent K m values for both CYP2C9*2 and CYP2C9*3 polymorphic variants was observed for all depicted substrate-enzyme pairs, with the exception of the Vivid ® CYP2C9 blue substrate and CYP2C9*3, in which no significant change in K m values compared to the wild type was discovered. The apparent V max value for the reaction of recombinant CYP2C9*3 with the Vivid ® CYP2C9 blue substrate dropped 3-fold compared to the wild type, resulting in a 75% reduction of the V max /K m ratio. Reduction of the V max /K m ratio for all the other substrates tested with CYP2C9*3 was less significant, running from a 25% to 50% reduction for the Vivid ® CYP2C9 green and blue substrates. In contrast, changes in the V max /K m ratio values for CYP2C9*2 were less significant with all the substrates tested. The highest drop of the V max /K m ratio for this variant was observed for the fluorogenic Vivid ® red substrate, resulting in an approximately 33% reduction compared to wild type.
Effects of solvents on assays employing fluorogenic Vivid ® substrates and CYP2C9*1, *2, and *3 polymorphic variants
Various organic solvents appeared to have a different effect on the reactions of CYP2C9*1, *2, and *3 with fluorogenic Vivid ® substrates (Figs. [2] [3] [4] . To determine if CYP2C9 polymorphic variants had different solvent sensitivity, assays were run as described in Materials and Methods, but each reaction contained varying amounts of one of the following solvents: DMSO, ACN, MeOH, or EtOH. Each reaction was performed with fluorogenic Vivid ® CYP2C9 blue, green, and red substrates, and the reaction rates in the presence of varying concentrations of organic solvent are expressed as a percentage of the reaction rates obtained in the absence of solvent ( Fig. 4) . Presence of 0.1% DMSO, ACN, MeOH, or EtOH did not significantly affect the reaction rates of Vivid ® CYP2C9 blue, green, and red substrates with all CYP2C9 polymorphic variants. Increased concentration of organic solvent in the reaction had various effects, depending on each enzymatic reaction.
Fluorogenic Vivid ® CYP2C9 green substrate
The 1% DMSO did not affect the reaction rates for CYP2C9*1, *2, and *3 with the fluorogenic Vivid ® CYP2C9 green substrate, but the presence of other organic solvents, such as 1% ACN, MeOH, or EtOH significantly lowered the reaction rates with the Vivid ® CYP2C9 green substrate for all polymorphic variants. The most significant changes were observed for CYP2C9*3, resulting in a 4-fold decrease in activity caused by 1% EtOH compared to the control rates obtained in the absence of solvent (Fig. 2) .
Fluorogenic Vivid ® CYP2C9 blue substrate
The reaction rates of CYP2C9*1, *2, and *3 with the fluorogenic Vivid ® CYP2C9 blue substrate were almost 50% lower in the presence of either 1% DMSO, MeOH, or EtOH. On the contrary, 1% ACN in the reaction with the fluorogenic Vivid ® CYP2C9 blue substrate resulted in a 25% increase in the reaction rates for CYP2C9*1 or *2 but not for CYP2C9*3 (Fig. 3) .
Fluorogenic Vivid ® CYP2C9 red substrate
The presence of either 1% MeOH or EtOH in the reaction with the fluorogenic Vivid ® red substrate affected the reaction rates with all 3 polymorphic variants, resulting in a 25% decrease in the rate for CYP2C9*2 and up to a 50% decrease for CYP2C9*1 and CYP2C9*3. The inhibitory effect of DMSO and ACN at 1% was less prominent for all polymorphic variants of CYP2C9 ( Fig. 4) .
Inhibitory potency of the selected drugs (apparent K i values) in the reaction of CYP2C9*1, *2, and *3 with the fluorogenic Vivid ® substrates The experimentally determined apparent K m values ( Table 2) for Vivid ® substrates with recombinant human CYP2C9 polymorphic variants were used as a guide to set appropriate screening concentrations of that substrate in subsequent competitive inhibition assays to identify the potency of assay modifiers (CYP2C9 substrates and inhibitors). The experiments were performed as described in Materials and Methods, and apparent K i values for each drug in the reaction with the CYP2C9 polymorphic variants and either the Vivid ® CYP2C9 green or red substrate were obtained. Apparent K i values in reactions with these fluorogenic substrates have been determined for a panel of the drugs previously implicated in CYP2C9 metabolism. The fluorogenic Vivid ® CYP2C9 blue substrate was excluded from the inhibition studies due to its high sensitivity to the presence of DMSO, an organic solvent most commonly used to dissolve drugs and compounds used in inhibition studies (Figs. 2-4) .
In reactions with both the fluorogenic Vivid ® CYP2C9 green and red substrates, apparent K i values at or below 0.1 µM were ob-HTS Assays for CYP2C9*1, *2, and *3 Metabolism tained for sulfaphenazole, a potent CYP2C9 inhibitor. 7, 13 In contrast, apparent K i values for tolbutamide and ibuprofen, other known CYP2C9 substrates, were in the range of 79 to 370 µM, representing lower affinity interactions (Table 3 ). Apparent K i values for the other drugs tested fell between these high-and lowaffinity values, allowing ranking of drugs by their inhibition potency. Despite the differences in the apparent K i values obtained with the Vivid ® CYP2C9 green or red assays, both assays predicted drug-ranking potency similarly (Table 3 , Fig. 5 ). Most important, apparent K i values in many reactions with both CYP2C9*2 and *3 varied significantly from the wild-type reactions.
Assays employing the fluorogenic Vivid ® CYP2C9 green and red substrates exhibit different sensitivity for the detection of the inhibitory potency of the selected drugs
To measure the extent of K i deviation as a result of polymorphism for a panel of drugs, a ratio of apparent K i values obtained with CYP2C9*2 and *3 relative to the wild type was calculated 
FIG. 4.
Vivid ® CYP2C9 red solvent tolerance using CYP2C9*1, CYP2C9*2, and CYP2C9*3.
( Fig. 5 ). The apparent K i values for drugs such as diclofenac, tolbutamide, ibuprofen, phenytoin, and (S)-warfarin were more than 2fold higher for CYP2C9*3 in both the Vivid ® CYP2C9 green and red fluorescent reporter reactions. In contrast, the apparent K i value for CYP2C9*3 and piroxicam was 2-to 3-fold lower (Fig.  5 ). Changes in apparent K i values for CYP2C9*2 were less significant for all drugs tested; 2-to 3-fold changes were observed for piroxicam (in the Vivid ® CYP2C9 green and red fluorescent reporter reaction) and diclofenac (in the Vivid ® CYP2C9 green fluorescent reporter reaction).
Assay dynamic range and Z factor
Assays employing the fluorogenic Vivid ® CYP2C9 green, blue, and red substrates exhibit a broad dynamic range (Table 4) and have high Z′ factors in a range of 0.7 to 0.89, making them suitable for HTS applications. 21
DISCUSSION
Individuals carrying polymorphic variants of major cytochrome P450 isozymes may exhibit altered drug metabolism and pharmacokinetic properties, leading to ADRs and toxicity for many clinically important drugs and for drug candidates in development. The ability to predict potential ADRs stemming from P450 polymorphism-related toxicity is one of the challenges of the modern drug discovery process. Here we report the development of HTS assays employing fluorogenic Vivid ® CYP2C9 substrates to profile compounds for CYP2C9-specific inhibition. We compared the performance of several polymorphic variants of CYP2C9: CYP2C9*1, *2, and *3 with the fluorogenic Vivid ® CYP2C9 blue, green, and red substrates based on several criteria, including apparent kinetic parameters (V max and K m ), solvent sensitivity, and apparent K i values of CYP2C9 assay modifiers (e.g., potential CYP2C9 substrates and inhibitors). CYP2C9*1, *2, and *3 BACULOSOMES ® reagents were active with the fluorogenic Vivid ® CYP2C9 red, blue, and green substrates, but the apparent kinetic parameters of each reaction were polymorphism dependent ( Table 2 ). CYP2C9*3 deviates the most significantly from wildtype CYP2C9 in apparent V max , K m , and V max /K m values for the CYP2C9 red and green substrates, while CYP2C9*2 exhibited less significant changes in all investigated parameters ( Table 2) . Although apparent K m values for the CYP2C9 blue substrate in the reaction with CYP2C9*2 were higher than in the corresponding CYP2C9*1 reaction, the V max /K m ratio for these 2 variants remained unchanged. These observations confirm previously reported findings about CYP2C9 polymorphic variants, indicating that the Leu359 mutation in CYP2C9*3 has a more significant effect on overall CYP2C9 activity by directly affecting the substratebinding site of this isozyme. 26 However, our data also indicate that the scale of this effect for both CYP2C9*2 and CYP2C9*3 is substrate dependent.
The choice of organic solvent used to solubilize drugs and test compounds can greatly affect enzyme activity. Our results demonstrate that various organic solvents affect CYP2C9*1, *2, and *3 reactions with Vivid ® CYP2C9 blue, green, and red substrates differently ( Figs. 2-4) , indicating that the solvent effect in these reactions depends on both the CYP2C9 polymorphic variant and the Vivid ® CYP2C9 substrate. In most cases, adding up to 0.1% organic solvent did not alter reaction rates of any the fluorogenic Vivid ® substrates with the polymorphic variants. However, when the solvent concentration was increased to 1%, the solvent effect became more prominent. Although in most cases, adding 1% solvent caused a significant decrease in reaction rates, in the case of the Vivid ® CYP2C9 blue substrate, adding 1% ACN increased the reaction rate by up to 25%. Such complex interactions with an organic solvent have been described previously for CYP3A4, 27 supplying more evidence for similar complex kinetic behaviors of these 2 isozymes. CYP2C9*3 tolerated the solvents tested the least in these reactions (DMSO, MeOH, EtOH, and ACN) compared to wild type, possibly indicating that the Leu359 substitution in the active center of CYP2C9 makes the polymorphic form more vulnerable to its environment. Apparent K i values obtained in the fluorescent reporter reaction with the fluorogenic Vivid ® CYP2C9 substrates were used as a measure of the relative affinity of the drug in the reaction with each CYP2C9 polymorphic variant (Table 3) . Obtaining information about the relative affinity of a particular drug can enable approximate comparisons with other relative affinity measurements, such as apparent K m or K d values obtained in vivo. CYP2C9*3 demonstrated the most significant changes in apparent K i values compared to wild type. The reduced affinity for CYP2C9*3 (higher apparent K i values) was observed with most but not with all CYP2C9 substrates (in a case of piroxicam, a reversed situation with lower apparent K i values for CYP2C9*3 was observed), indicating a need for individual assessment of each drug implicated in CYP2C9 polymorphism (Table 3) .
Differences in apparent K m values for diclofenac hydroxylation, measured by a conventional high-performance liquid chromatography (HPLC) assay, have been reported previously with yeast-expressed recombinant CYP2C9 where K m values in a range of 7.0 to 7.7 µM for CYP2C9*1, 5.0 to 6.1 µM for CYP2C9*2, and 22 to 26 µM for CYP2C9*3 polymorphic variants were obtained. 7 Apparent K i values obtained for diclofenac in Vivid ® CYP2C9 green and red assays were as follows: 0.35 to 0.7 µM for CYP2C9*1, 0.8 to 1.6 µM for CYP2C9*2, and 2.6 to 3.9 µM for CYP2C9*3 ( Table 3 ). Although the apparent K i values obtained for diclofenac with Vivid ® fluorogenic substrates (Table 3) were lower than reported K m values for diclofenac, similar effects have been seen previously in attempts to correlate IC 50 values obtained in assays with fluorescent and conventional substrates. 28 For example, IC 50 values obtained for sulfaphenazole in assays using 7methoxy-4-trifluoromethylcoumarin (MFC), another fluorescent CYP2C9 substrate, were 7-to 12-fold lower compared to IC 50 values obtained in the conventional assay. 28 Since apparent IC 50 values obtained with fluorogenic substrates for CYP2C9 are generally lower than those obtained with conventional probes, a statistical extrapolation of the values between the 2 systems is not advisable. 28 At the same time, by using the HTS assay with fluorogenic substrates, it is possible to rank drugs and compounds by their potency to inhibit or activate the fluorescent reporter reaction 29 and to follow up on possible changes in this ranking due to a polymorphism. Particularly relevant to CYP2C9 polymorphism screening is the observation that both types of assays (fluorescent and conventional) revealed a similar trend of relative increase in K m values (diclofenac HPLC assay) and apparent K i values (Vivid ® green and red assays) for CYP2C9*3 compared to the wild type.
For the majority of drugs tested, drug ranking by inhibitory potency was comparable with both the Vivid ® CYP2C9 green and red assays (Fig. 5 ), but not with the Vivid ® CYP2C9 blue assay, which was excluded from inhibition studies due to its high sensitivity to the presence of DMSO, an organic solvent most commonly used to dissolve tested drugs and compounds in inhibition studies (Figs. [2] [3] [4] . As a general rule, the relative compound potency data obtained with either the Vivid ® CYP2C9 green or red substrate were transferable to studies performed with the other substrate. At the same time, apparent K i values for diclofenac obtained with Vivid ® CYP2C9 green substrate (Table 3 ) had a better correlation with diclofenac 4′-hydroxylation assay results, 7 therefore suggesting a preference for the green substrate application in initial screening of CYP2C9 assay modifiers in the HTS format. However, due to differences in fluorescent excitation and emission spectra of the oxidized product (Table 1) , each Vivid ® substrate may have particular advantages in screening compound libraries, especially when fluorescent compound interference is suspected. The Vivid ® assay format allows prescreening of compound libraries for initial fluorescence prior to addition of the other assay components. Once a compound's fluorescence has been detected at the initial stage, a Vivid ® substrate can be chosen with excitation and emission wavelengths distinct from those of the compound's to reduce potential interference with Vivid ® metabolite detection. The latter observation suggests that particular characteristics of each Vivid ® CYP2C9 substrate may allow more sensitive detection of certain classes of molecular structures and their interactions with particular enzymes (Fig. 5 ).
In addition, an interesting phenomenon has been observed with compounds such as ibuprofen, exhibiting heteroactivation potency in the assay with CYP2C9*3 and Vivid ® red substrate but acting as an inhibitor in the green assay (Table 3 ). Similar effects have been previously documented for other CYP2C9 substrates. For example, niclosamide, which appeared to be a potent inhibitor of CYP2C9-mediated diclofenac-4-hydroxylase activity, was also reported to be a potent activator of 7-methoxy-4-trifluoromethylcoumarin (MFC) metabolism. 30 Substrate-dependent effects were also observed with phenytoin, exhibiting similar apparent K i values for all 3 polymorphic variants with CYP2C9 green substrate, but more than 10-fold lower affinity for CYP2C9*3 was detected with the red substrate compared to CYP2C9*1. It is important to note that phenytoin has nonlinear and dose-dependent pharmacokinetic properties, has a narrow therapeutic range, 31 and is involved in well-documented cases of clinical toxicity as a result of drug-drug interactions. 32 Therefore, it is possible that the lower affinity of phenytoin observed in the Vivid ® red assay with CYP2C9*3 (Table 3 ) could be an indicator of potentially important clinical drug interactions, especially for CYP2C9*3 polymorphic variant carriers, but this remains to be studied. In conclusion, the obvious substrate-dependent effects suggest applications of more than 1 substrate in CYP2C9 effector screening aimed at predicting clinical drug interaction potential. 29 Apparently, differences in K i values obtained in reactions with different Vivid ® substrates (Table 3 ) may reflect strong substratedependent effects previously observed for several CYP2C9 reac-tions. 28, 29, 33 As a result of the obvious substrate-dependent effects, direct extrapolation of the in vitro data obtained with Vivid ® fluorogenic substrates to in vivo situations may not be possible. Although similar difficulties have been previously reported in attempts to correlate in vitro and in vivo data obtained with several other P450 enzymes and substrates, 5 these issues do not negate the overall concept of ranking compounds based on their inhibitory potency. One drawback of the described assays is that they do not allow assessment of the intrinsic clearance rates for each specific drug but detect only changes in substrate-binding properties. However, the assays can serve as a simple and effective HTS primary screen of compound libraries with polymorphic variants to identify those compounds with altered affinity for a particular polymorphic variant. Further validation of the compounds identified in a primary screen may include secondary low-throughput assays and in vivo studies.
CONCLUSIONS
The fluorogenic Vivid ® P450 substrates have been applied successfully to study the metabolism and inhibition of various P450 isozymes. 22, 23 Here we present the first evidence that these substrates can be successfully applied to study variation in metabolism due to a polymorphism in selected cytochrome P450 isozymes. Several methods for assessment of the drug-related polymorphism on a genetic level are currently available, including oligonucleotide microarrays and HTS DNA sequencing. 34, 35 However, these methods do not allow evaluation of the functional polymorphism (e.g., assessing whether a particular polymorphic variant will exhibit altered rates of drug metabolism for a particular drug and therefore will be of clinical significance for a medication). In this study, we employed the fluorogenic Vivid ® CYP2C9 green and red substrates in fluorescence-based HTS assays with polymorphic variants of recombinant human CYP2C9 enzyme, allowing functional characterization of the polymorphism. We used these assays to evaluate the inhibitory potency of a selected panel of pharmaceutical agents, including drugs known to be metabolized by CYP2C9. Assays employing the fluorogenic Vivid ® substrates provide a quick and sensitive assessment of the relative affinity of the tested drug for the CYP2C9 polymorphic variant by estimating the apparent K i value for that drug in the fluorescent reporter reaction in the HTS format. This assessment allows identification and ranking of compounds based on their deviation from the relative affinity calculated for the wild-type CYP2C9 isozyme as a firstline approach for evaluating the role of CYP2C9 polymorphisms and their impact on metabolism. Although the current investigation was limited to the application of Vivid ® fluorogenic substrates for the study of CYP2C9 polymorphism and did not include crossinhibition studies related to CYP2C9 cooperativity, it remains to be seen if there is value in applying structurally diverse Vivid ® substrates for future cross-inhibition studies that may support the positive cooperativity model of CYP2C9 binding as previously reported. 36 
